Literature DB >> 12069027

Hepatic actinomycosis: an overview of salient features and outcome of therapy.

Mamta Sharma1, Laurence E Briski, Riad Khatib.   

Abstract

A 34-y-old African-American male developed Actinomyces liver abscess 8 months after appendectomy. Review of the English language literature revealed 56 additional cases of hepatic actinomycosis. Affected patients were typically immunocompetent, had a wide age range (4-86 y) and were predominantly male (70.2%). Infection was frequently (80.7%) cryptogenic, presenting with fever (83.3%), abdominal pain (74.5%) and weight loss (50.9%) over a 3.7 +/- 5.1 month period. The most common radiographic finding was a single hypodense mass/abscess (68.4%). Extension to surrounding tissues was evident in 19 cases (33.3%). Diagnosis was usually accomplished microscopically and culture was often (33.3%) negative. Infection was often (35.2%) mixed, usually with anaerobic bacteria. A surgical or percutaneous approach was diagnostic in 29/35 (82.9%) and 24/33 (72.7%) cases, respectively. The overall mortality rate was 8.8%; it was 10.7% with medical therapy alone and 4.0% using a combined medical/intervention approach (p = 0.6). In conclusion, hepatic actinomycosis is a rare subacute infection that may mimic neoplasm. It is usually cryptogenic, is more common among immunocompetent individuals and male subjects and is highly responsive to medical therapy.

Entities:  

Mesh:

Year:  2002        PMID: 12069027     DOI: 10.1080/00365540110080304

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  18 in total

1.  Abdominal actinomycosis simulating malignancy of the right colon.

Authors:  Burak Işik; Engin Aydin; Gokhan Sogutlu; Cengiz Ara; Sezai Yilmaz; Vedat Kirimlioglu
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

Review 2.  Hepatic actinomycosis: report of one case and analysis of 32 previously reported cases.

Authors:  Xing-Xiang Yang; Jian-Mei Lin; Kai-Ju Xu; Shu-Qiang Wang; Ting-Ting Luo; Xiao-Xia Geng; Ren-Gang Huang; Nan Jiang
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

3.  Primary Hepatic Actinomycosis Mimicking Hepatic Malignancy with Metastatic Lymph Nodes by F-18 FDG PET/CT.

Authors:  Eun Jung Kong
Journal:  Nucl Med Mol Imaging       Date:  2015-07-07

4.  Isolated hepatic actinomycosis: a case report.

Authors:  Thomas Lall; Thomas M Shehab; Paul Valenstein
Journal:  J Med Case Rep       Date:  2010-02-08

5.  Actinomycotic hepatic abscess.

Authors:  Arzu Tiftikci; Eser N Vardareli; Kerim Kaban; Onder Peker; Sertac Akansel; Nurdan Tozun
Journal:  Hepatol Int       Date:  2007-11-29       Impact factor: 6.047

6.  Pelvic actinomycosis-like disease due to Propionibacterium propionicum after hysteroscopic removal of an intrauterine device.

Authors:  Herman F Wunderink; Eileen E L O Lashley; Mariëtte I E van Poelgeest; Katja N Gaarenstroom; Eric C J Claas; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

7.  Thoraco-pulmonary and hepatic actinomycosis: an autopsy report.

Authors:  George Powell; Manel Mangalika
Journal:  BMJ Case Rep       Date:  2011-11-08

8.  Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen.

Authors:  Janine Reichenbach; Uri Lopatin; Nizar Mahlaoui; Bojana Beovic; Ulrich Siler; Reinhard Zbinden; Reinhard A Seger; Louise Galmiche; Nicole Brousse; Samer Kayal; Tayfun Güngör; Stéphane Blanche; Steven M Holland
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

9.  Post varicella hepatic actinomycosis in a 5-year-old girl mimicking acute abdomen.

Authors:  Ahmet Guven; Vural Kesik; M Salih Deveci; M Sahin Ugurel; Haluk Ozturk; Vedat Koseoglu
Journal:  Eur J Pediatr       Date:  2007-12-06       Impact factor: 3.183

10.  Primary liver actinomycosis in a pediatric patient: A case report and literature review.

Authors:  Zi-Jian Liang; Jian-Kun Liang; Yun-Pei Chen; Zhen Chen; Yong Wang
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.